Zynerba Pharmaceuticals Inc

Change company Symbol lookup

Select an option...

ZYNE Zynerba Pharmaceuticals Inc

AR Antero Resources Corp

PAYX Paychex Inc

AEHL Antelope Enterprise Holdings Ltd

NOV Nov Inc

GLDG GoldMining Inc

SOJC Southern Co

NYCB New York Community Bancorp Inc

USLM United States Lime & Minerals Inc

KAVL Kaival Brands Innovations Group Inc

Go

Zynerba Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company. The Company is focused on the development of pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, including Fragile X syndrome (FXS), autism spectrum disorder (ASD), 22q11.2 deletion syndrome (22q), and a heterogeneous group of rare epilepsies known as developmental and epileptic encephalopathies (DEE). Its lead product candidate, Zygel (ZYN002 CBD Gel) is a cannabidiol (CBD) gel for FXS, ASD in pediatric patients, 22q, and a heterogeneous group of rare epilepsies known as DEE. Its clinical program for Zygel includes clinical trials evaluating Zygel in the treatment of behavioral symptoms of FXS, ASD and 22q and the reduction of seizures and the treatment of associated symptoms in patients with DEE syndromes.